Windtree Therapeutics, Inc. SG&A Expenses

SG&A Expenses of WINT for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative


Highlights and Quick Summary

  • SG&A Expenses for the quarter ending June 29, 2020 was $3.45 Million (a 6.51% increase compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses increased by 1.71%
  • Annual SG&A Expenses for 2019 was $12.4 Million (a 67.15% increase from previous year)
  • Annual SG&A Expenses for 2018 was $7.42 Million (a 11.48% increase from previous year)
  • Annual SG&A Expenses for 2017 was $6.66 Million (a -20.49% decrease from previous year)
  • Twelve month SG&A Expenses ending June 29, 2020 was $12.5 Million (a 1.73% increase compared to previous quarter)
  • Twelve month trailing SG&A Expenses decreased by -2.14% year-over-year
Trailing SG&A Expenses for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
$12.5 Million $12.3 Million $12.4 Million $12.8 Million
Visit stockrow.com/WINT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of Windtree Therapeutics, Inc.

Most recent SG&A Expensesof WINT including historical data for past 10 years.

Interactive Chart of SG&A Expenses of Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $3.45 $3.24
2019 $2.41 $3.4 $3.24 $3.36 $12.4
2018 $2.79 $1.5 $1.21 $1.93 $7.42
2017 $1.18 $1.75 $1.8 $1.92 $6.66
2016 $1.32 $1.61 $1.78 $3.66 $8.37
2015 $2.21 $2.06 $3.38 $3.35 $11.0
2014 $3.74 $4.13 $4.45 $4.42 $16.73
2013 $4.07 $4.3 $4.13 $4.22 $16.72
2012 $6.53 $4.26 $3.61 $2.05 $16.44
2011 $1.89 $2.19 $1.97 $1.82 $7.86
2010 $2.12 $1.48 $1.87 $2.93 $8.39

Business Profile of Windtree Therapeutics, Inc.

Sector: Medical
Industry: Drugs
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.